Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/AP2B1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AP2B1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AP2B1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AP2B1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AP2B1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/AP2B1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AP2B1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AP2B1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AP2B1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AP2B1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000182213 | Prostate | Tumor | kidney development | 74/3246 | 293/18723 | 3.68e-04 | 2.87e-03 | 74 |
GO:007200113 | Prostate | Tumor | renal system development | 75/3246 | 302/18723 | 5.74e-04 | 4.13e-03 | 75 |
GO:00032311 | Prostate | Tumor | cardiac ventricle development | 36/3246 | 123/18723 | 7.31e-04 | 5.08e-03 | 36 |
GO:000328111 | Prostate | Tumor | ventricular septum development | 23/3246 | 71/18723 | 1.47e-03 | 9.08e-03 | 23 |
GO:000320511 | Prostate | Tumor | cardiac chamber development | 43/3246 | 161/18723 | 1.86e-03 | 1.09e-02 | 43 |
GO:003162313 | Prostate | Tumor | receptor internalization | 32/3246 | 113/18723 | 2.51e-03 | 1.40e-02 | 32 |
GO:009907212 | Prostate | Tumor | regulation of postsynaptic membrane neurotransmitter receptor levels | 20/3246 | 62/18723 | 3.07e-03 | 1.63e-02 | 20 |
GO:000327911 | Prostate | Tumor | cardiac septum development | 29/3246 | 103/18723 | 4.26e-03 | 2.13e-02 | 29 |
GO:190121514 | Prostate | Tumor | negative regulation of neuron death | 51/3246 | 208/18723 | 5.24e-03 | 2.52e-02 | 51 |
GO:190382927 | Skin | AK | positive regulation of cellular protein localization | 64/1910 | 276/18723 | 2.23e-10 | 3.00e-08 | 64 |
GO:190547520 | Skin | AK | regulation of protein localization to membrane | 37/1910 | 175/18723 | 1.33e-05 | 2.62e-04 | 37 |
GO:007099728 | Skin | AK | neuron death | 63/1910 | 361/18723 | 1.50e-05 | 2.94e-04 | 63 |
GO:190121425 | Skin | AK | regulation of neuron death | 57/1910 | 319/18723 | 1.87e-05 | 3.52e-04 | 57 |
GO:190547720 | Skin | AK | positive regulation of protein localization to membrane | 24/1910 | 106/18723 | 1.38e-04 | 1.69e-03 | 24 |
GO:000165510 | Skin | AK | urogenital system development | 54/1910 | 338/18723 | 5.86e-04 | 5.20e-03 | 54 |
GO:00032313 | Skin | AK | cardiac ventricle development | 25/1910 | 123/18723 | 5.89e-04 | 5.21e-03 | 25 |
GO:003010019 | Skin | AK | regulation of endocytosis | 36/1910 | 211/18723 | 1.42e-03 | 1.05e-02 | 36 |
GO:00032815 | Skin | AK | ventricular septum development | 16/1910 | 71/18723 | 1.80e-03 | 1.24e-02 | 16 |
GO:004580719 | Skin | AK | positive regulation of endocytosis | 20/1910 | 100/18723 | 2.43e-03 | 1.59e-02 | 20 |
GO:00315036 | Skin | AK | protein-containing complex localization | 36/1910 | 220/18723 | 2.97e-03 | 1.87e-02 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AP2B1 | SNV | Missense_Mutation | novel | c.496N>T | p.Arg166Trp | p.R166W | P63010 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AP2B1 | SNV | Missense_Mutation | novel | c.1399N>C | p.Glu467Gln | p.E467Q | P63010 | protein_coding | tolerated(0.1) | benign(0.054) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
AP2B1 | SNV | Missense_Mutation | novel | c.2654N>G | p.Asn885Ser | p.N885S | P63010 | protein_coding | tolerated(0.84) | benign(0.024) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
AP2B1 | insertion | Nonsense_Mutation | novel | c.2252_2253insGTTCTTCCCAATCTCCCCTCTCCCTT | p.Tyr751Ter | p.Y751* | P63010 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AP2B1 | insertion | In_Frame_Ins | novel | c.1761_1762insGTTAAAAAAAATTTCTTTTTTTTGGAACGGAGTTTTGCTCTT | p.Gly587_Ile588insValLysLysAsnPhePhePheLeuGluArgSerPheAlaLeu | p.G587_I588insVKKNFFFLERSFAL | P63010 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AP2B1 | insertion | Nonsense_Mutation | novel | c.1730_1731insATTATAGGCATGTGCCACCTTGCCTGGCTAATTTTTTGTATT | p.Pro577_Pro578insLeuTerAlaCysAlaThrLeuProGlyTerPhePheValPhe | p.P577_P578insL*ACATLPG*FFVF | P63010 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
AP2B1 | SNV | Missense_Mutation | novel | c.2636N>T | p.Ser879Phe | p.S879F | P63010 | protein_coding | tolerated(0.07) | possibly_damaging(0.867) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AP2B1 | SNV | Missense_Mutation | novel | c.1142N>T | p.Ala381Val | p.A381V | P63010 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AP2B1 | SNV | Missense_Mutation | novel | c.1715C>T | p.Ser572Phe | p.S572F | P63010 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AP2B1 | SNV | Missense_Mutation | novel | c.1501N>A | p.Glu501Lys | p.E501K | P63010 | protein_coding | tolerated(0.22) | benign(0.027) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |